347 related articles for article (PubMed ID: 25814671)
1. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome.
Rizzo AN; Aman J; van Nieuw Amerongen GP; Dudek SM
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1071-9. PubMed ID: 25814671
[TBL] [Abstract][Full Text] [Related]
2. Abl family kinases regulate endothelial barrier function in vitro and in mice.
Chislock EM; Pendergast AM
PLoS One; 2013; 8(12):e85231. PubMed ID: 24367707
[TBL] [Abstract][Full Text] [Related]
3. Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury.
Letsiou E; Rizzo AN; Sammani S; Naureckas P; Jacobson JR; Garcia JG; Dudek SM
Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(3):L259-69. PubMed ID: 25480336
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of edema and endothelial barrier dysfunction with imatinib.
Aman J; van Bezu J; Damanafshan A; Huveneers S; Eringa EC; Vogel SM; Groeneveld AB; Vonk Noordegraaf A; van Hinsbergh VW; van Nieuw Amerongen GP
Circulation; 2012 Dec; 126(23):2728-38. PubMed ID: 23099479
[TBL] [Abstract][Full Text] [Related]
5. Arg mediates LPS-induced disruption of the pulmonary endothelial barrier.
Rizzo AN; Belvitch P; Demeritte R; Garcia JGN; Letsiou E; Dudek SM
Vascul Pharmacol; 2020; 128-129():106677. PubMed ID: 32240815
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase.
Stephens RS; Servinsky LE; Rentsendorj O; Kolb TM; Pfeifer A; Pearse DB
Am J Physiol Cell Physiol; 2014 Mar; 306(6):C559-69. PubMed ID: 24401847
[TBL] [Abstract][Full Text] [Related]
7. Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages.
Greuber EK; Pendergast AM
J Immunol; 2012 Dec; 189(11):5382-92. PubMed ID: 23100514
[TBL] [Abstract][Full Text] [Related]
8. Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function.
Dudek SM; Chiang ET; Camp SM; Guo Y; Zhao J; Brown ME; Singleton PA; Wang L; Desai A; Arce FT; Lal R; Van Eyk JE; Imam SZ; Garcia JG
Mol Biol Cell; 2010 Nov; 21(22):4042-56. PubMed ID: 20861316
[TBL] [Abstract][Full Text] [Related]
9. Abl family nonreceptor tyrosine kinases modulate short-term synaptic plasticity.
Moresco EM; Scheetz AJ; Bornmann WG; Koleske AJ; Fitzsimonds RM
J Neurophysiol; 2003 Mar; 89(3):1678-87. PubMed ID: 12626632
[TBL] [Abstract][Full Text] [Related]
10. [Experimental advance of targeted medicines for chronic myeloid leukemia--review].
Yang DG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):211-4. PubMed ID: 17490557
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
Kłosowska-Wardęga A; Hasumi Y; Åhgren A; Heldin CH; Hellberg C
Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension.
Woodring PJ; Litwack ED; O'Leary DD; Lucero GR; Wang JY; Hunter T
J Cell Biol; 2002 Mar; 156(5):879-92. PubMed ID: 11864995
[TBL] [Abstract][Full Text] [Related]
13. Abl knockout differentially affects p130 Crk-associated substrate, vinculin, and paxillin in blood vessels of mice.
Chen S; Wang R; Li QF; Tang DD
Am J Physiol Heart Circ Physiol; 2009 Aug; 297(2):H533-9. PubMed ID: 19542491
[TBL] [Abstract][Full Text] [Related]
14. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
[TBL] [Abstract][Full Text] [Related]
15. Endothelial p110γPI3K Mediates Endothelial Regeneration and Vascular Repair After Inflammatory Vascular Injury.
Huang X; Dai Z; Cai L; Sun K; Cho J; Albertine KH; Malik AB; Schraufnagel DE; Zhao YY
Circulation; 2016 Mar; 133(11):1093-103. PubMed ID: 26839042
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
18. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
[TBL] [Abstract][Full Text] [Related]
19. Imatinib Alters Agonists-mediated Cytoskeletal Biomechanics in Lung Endothelium.
Wang X; Bleher R; Wang L; Garcia JGN; Dudek SM; Shekhawat GS; Dravid VP
Sci Rep; 2017 Oct; 7(1):14152. PubMed ID: 29075042
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
